In experiments with mice, researchers at Johns Hopkins Medicine report a promising advance in the search for a new class of drugs to treat major depression.
While treatments for rheumatoid arthritis have traditionally focused on targeting the disease’s inflammatory pathways, increasingly, research is pointing to a need to account for the role of autoantibodies in disease progression. One example: some people have a more highly active form of the disease that can lead to worse outcomes if left untreated or under-treated. […]
J. Michael Pearson has become a billionaire from his tough tactics as the head of the fast-growing Valeant Pharmaceuticals International. And consumers like Bruce Mannes, a 68-year-old retired carpenter from Grandville, Mich., are facing the consequences. Mr. Mannes has been taking the same drug, Cuprimine, for 55 years to treat Wilson disease, an inherited disorder […]
U.S. DRUG COMPANY ALEXION IS SUING THE CANADIAN GOVERNMENT OVER PRICING OF SOLIRIS: CBC NEWS Sept 24 2015
A U.S. drug company is taking the Canadian government to court for its attempt to lower the price of what has been called the world’s most expensive drug. Alexion Pharmaceuticals has filed a motion in Federal Court, arguing that Canada’s drug price watchdog has no authority to force the company to lower its price for […]
Spotlight on Alexion’s pricing of rare-disease drug Soliris Cost of one of world’s most expensive drugs shrouded in corporate secrecy By Kelly Crowe, CBC News Posted: Jun 25, 2015 5:00 AM ET Last Updated: Jun 25, 2015 5:00 AM ET About The Author Kelly Crowe Medical science Kelly Crowe is a medical sciences correspondent for CBC […]
TAKING PATIENT ASSISTANCE PROGRAMS TO THE NEXT LEVEL: Raymond Rupert MD. MBA. Rupert Case Management Inc. 800 620 7551 INTRODUCTION TO BIOLOGICS: Biologics change everything. Smart medications that target the source of the disease are the foundation for personalized medicine. The treatment outcomes can be outstanding. Unfortunately, these medications are expensive and this has lead […]